CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

Similar documents
CHEMOTHERAPY APR. 1982



CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)


CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk


Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL. 36 S Fig. 1 Chemical structures of cefotiam hexetil and related compounds

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Fig.1 Chemical structure of BAY o 9867

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY

CHEMOTHERAPY APR. 1984

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL. 34 S-2 CHEMOTH8RAPY 913

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

CHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemica

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin



CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

Fig. 1 Chemical structure of KW-1070

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

Continuous Cooling Transformation Diagrams for Welding of Mn-Si Type 2H Steels. Harujiro Sekiguchi and Michio Inagaki Synopsis: The authors performed


Key words: Surfactant, Tween, Legionella

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


報告書 H22-2A-09

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia



VOL. 36 S-3 CHEMOTHERAPY 437

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

Introduction ur company has just started service to cut out sugar chains from protein and supply them to users by utilizing the handling technology of

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K



Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

VOL.42 S-1

Table1MIC of BAY o 9867 against standard strains

CHEMOTHERAPY FEB Table 1 Background of volunteers

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

VOL.39 S-3

VOL. 21 NO. 2 CHEMOTHERAPY 137

CHEMOTHERAPY SEPT. 1970



Fig. 1 Chemical structure of norfioxacin (AM-715)

平成26年度 化学物質分析法開発報告書

CHEMOTHERAPY OCT. 1993

Oxidative Dimerization of Tocopherols in Saturated and Unsaturated Triglycerides. III Formation of 5-(ƒÂ-Tocopheroxy)-ƒÂ-5-tocopherol and 5-(ƒÂ-Tocoph


VOL. 25 NO. 6 CHEMOTHERAPY 1667

Motivation and Purpose There is no definition about whether seatbelt anchorage should be fixed or not. We tested the same test conditions except for t

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

1. Precise Determination of BaAl2O4 Cell and Certification of the Formation of Iron Bearing Solid Solution. By Hiroshi UCHIKAWA and Koichi TSUKIYAMA (



平成26年度 化学物質分析法開発報告書

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

** Department of Materials Science and Engineering, University of California, Los Angeles, CA 90025, USA) Preparation of Magnetopulmbite Type Ferrite


Takio ICHITANI and Teruko HIGASHIKAWA: Germination of Aphanomyces iridis oospores on the basal medium for selective isolation with addition of bacteri


CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str


技術研究所 研究所報 No.80

Study on Application of the cos a Method to Neutron Stress Measurement Toshihiko SASAKI*3 and Yukio HIROSE Department of Materials Science and Enginee

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit


CHEMOTHERAPY

CHEMOTHERAPY SEPT. 1991

Key words: Salmonella Typhi, Water borne infection.


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Transcription:

CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column Nucleosil 5C18 (150mm ~4mm) Column temp. 40 `45 Ž Mobile phase 0.1M NaH2PO4: CH3CN= 92: 8 Flow rate 1.0 `1.4ml/min Pressure 1600 `2000 p. s. i. Detector UV (280nm) Fig. 3 Comparison of standard curves of CTT on various test organisms Diluent: by agar well method Human plasma Fig. 4 Comparison of standard curves of CTT on various test medium by disc plate method

CHEMOTHERAPY APR. 1982 Fig. 5 Effect of medium ph on standard curves of CTT by disc plate method Fig. 6 Comparison of standard curves of CTT on various inoculum sizes using E. coli NIHJ (Disc plate method) Fig. 7 Comparison of standard curves of CTT on various prediffusion time at 4 Ž by disc plate method

VOL.30 S-1 CHEMOTHERAPY Fig. 8 Effect of diluents on standard curves of CTT by disc plate method Fig. 9 Effect of diluents on standard curves of CTT by disc plate method Fig. 10 Effect of diluents on standard curves of m by disc plate method

102 CHEMOTHERAPY APR. 1982 Fig. 11 Effect of diluents on standard curves of CTT by disc plate method Concentration of CTT (Đg/m1) Fig. 12 Comparison of standard curves of CTT on various assay method Test organism: E. coli NIHJ Concentration of CTT (Đg/ml) Fig. 13 Stability of CTT in human plasma Test organism: E. coil NIHJ Method: Disc plate method

VOL.30 S-1 CHEMOTHERAPY Fig. 14 Stability of CTT in human urine Method: Disc plate method Fig. 15 Stability of CTT in rat bile Method: Disc plate, method

CHEMOTHERAPY APR. 1982 1) YANO, K.; K. SUZAKI, M. SAITO, M. TODA, T. SAITO& S. MITSUHASHI In vitro and in vivo antibacterial activities of YM09330, a new cephamycin derivative. 11th International Congress of Chemotherapy and 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. No. 564, 1979 2) YANO, K.; K. SUZAKI, M. TODA, T. SAITO& S. MITSUHA. SHI: Ĉ- Lactamase inhibitory activity of YM09330. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. No. 159, 1980 6) TACHIBANA, A.; M. KOMIYA, Y. KIKUCHI, K. YANO& K. MASHIMO Pharmacological studies on YM09330, a new parenteral cephamycin derivative. 11th International Congress of Chemotherapy and 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. No. 563, 1979

VOL.30 S-1 CHEMOTHERAPY MICROBIOLOGICAL ASSAY METHODS OF CEFOTETAN (YM09330) CONCENTRATIONS IN BODY FLUIDS MASAYUKI KOMIYA, YASUHIRO KIKUCHI, AKIO TACHIBANA and KUNIICHIRO YANO Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd. The microbiological assay methods for antibiotic concentration in body fluids after treatment of cefotetan (CTT, YM09330), a new semisynthetic cephamycin antibiotic, were discribed. The suitable conditions for the assay of the concentration resulted from using of E. coli NIHJ as the test organism and sensitivity test agar as the medium, in which 1% of over-night precultured Trypticase soy broth inoculated with the test organism was added. For the determination of the antibiotic concentration in biological specimens, three assay methods, thin- layer cup, thin- layer disc and agar well method, gave the suitable long- range standard curves and revealed good sensitivity. Cefotetan standard curve was not markedly influenced by ph of the medium and of the diluent buffer solution. By the thin- layer disc method, the detectable concentrations of cefotetan were, at the lowest, 0.2 ƒêg/ ml for 1/ 10M phosphate buffer ph 7.0, and 0.78 jig/ ml for human plasma, Consera and Moni- trol I when used as the diluent for the standard solution. The inhibition zone sizes of cefotetan dissolved in human plasma, Consera and Moni- trol I were smaller than those in phosphate buffer solution at ph 7.0. However, the standard curves of cefotetan using human plasma and Consera as the diluent showed almost the same figure. The concentrations of cefotetan in urine and bile detected by the bioassay method were in good agreement with those obtained by HPLC method. Cefotetan was stable in phosphate buffer solution at ph 7.0, human plasma and human urine at-20 Ž over a period of 30 days. In rat bile, cefotetan was unstable somewhat at 4 Ž but was stable during 7 days storage at-20 Ž.